News and Trends 12 Oct 2022 WuXi Biologics and Toregem BioPharma to develop antibody for adentia treatment WuXi Biologics and Toregem BioPharma, a biotech startup company from Kyoto University, have signed a memorandum of understanding to form a strategic partnership to develop TRG035. TRG035 is a monoclonal antibody targeting USAG-1 as a tooth regeneration treatment for congenital adentia. Within the partnership, Toregem BioPharma will have access to WuXi Biologics’ integrated CMC services […] October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial TILT Biotherapeutics says the first U.S. patient has been dosed in its ovarian cancer trial using its oncolytic adenovirus, TILT-123. The company said TILT-123 has the potential to be first-in-class for this indication. The open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s (a tradename of Merck & Co., […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’ Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Gedea Biotech reports results from bacterial vaginosis trial Gedea Biotech has reported top-line results from a clinical study, NEFERTITI, of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). NEFERTITI is a placebo-controlled, double blind clinical trial performed in Sweden and UK in 150 patients. Treatment details The treatment is a vaginal tablet taken once daily for six […] October 11, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Muna Therapeutics gets $4.9M grant for Parkinson’s disease research Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying […] October 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Positive results from NMD Pharma myasthenia gravis trial NMD Pharma A/S has reported positive top-line results from its phase I/IIa clinical trial of NMD670, recently granted orphan drug designation by the FDA for treatment of myasthenia gravis (MG). NMD670 was safe and well tolerated in healthy volunteers and patients. Administration of single doses of NMD670 was associated with clinically significant improvements in the […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Clinical Microbiomics expanding with €10M million investment Danish microbiome research company Clinical Microbiomics A/S has received €10 million ($9.7 million) in funding from Seventure Partners. Clinical Microbiomics, founded in 2015, is a microbiome analysis company, which includes work on clonal-level microbiome profiling. The company is working with food and consumer health companies and is supporting the pharmaceutical industry in phase 3 clinical […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Fast track designation for Nanoscope Therapeutics’ retinitis pigmentosa treatment Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, says the U.S. Food and Drug Administration (FDA) has granted fast track designation (FTD) to MCO-010. MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal […] October 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug China’s National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection. Also known as relma-cel, the product has the trade name Carteyva. It is used for the treatment of adult patients with follicular lymphoma that is […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Evonik and Phathom Pharmaceuticals partner on novel acid-blocker vonoprazan Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharma company developing and commercializing new treatments for gastric acid-related diseases. Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, U.S., and Dossenheim, Germany. “The manufacture of vonoprazan requires multi-step syntheses involving complex chemistries. We are […] October 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Biocartis starts European commercialization of liver cancer test Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Chinese company sees approval for diabetes drug Hua Medicine says its new drug application (NDA) for HuaTangNing (dorzagliatin tablets) has been approved by the National Medical Products Administration (NMPA) in China. HuaTangNing is a first-in-class glucokinase activator (GKA) developed by the company. The approval is for two indications, both to improve blood glucose control for type 2 diabetes (T2D) patients, as monotherapy […] October 10, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email